### Oseltamivir

#### Indication
Influenza due to identified seasonal influenza virus

<table>
<thead>
<tr>
<th>INN</th>
<th>Oseltamivir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>List type</td>
<td>Complementary</td>
</tr>
<tr>
<td>Additional notes</td>
<td>*severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients.</td>
</tr>
</tbody>
</table>

#### Formulations
- Oral > Liquid: 12 mg per mL powder for oral liquid
- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

#### EML status history
- First added in 2011 (TRS 965)
- Changed in 2013 (TRS 985)
- Changed in 2017 (TRS 1006)
- Changed in 2019 (TRS 1021)

#### Sex
- All

#### Age
- Also recommended for children

#### Therapeutic alternatives
- The recommendation is for this specific medicine

#### Patent information
Read more about patents. [Read more](#)

#### Wikipedia
- Oseltamivir [Read more](#)

#### DrugBank
- Oseltamivir [Read more](#)

---

**Summary of evidence and Expert Committee recommendations**

The Committee noted the advice from the WHO Secretariat that the WHO Guidelines for clinical management of influenza are in the process of being updated, but the recommendations of the guideline development group were not yet available. The Committee recommended that no change be made to the current listing for oseltamivir on the Model Lists until the updated guidelines and supporting evidence can be reviewed.